8-K: Fulgent Genetics Reports Mixed Q4 and Full Year 2024 Results; Core Revenue Growth Offset by GAAP Losses

Fulgent Genetics announces its Q4 and full year 2024 financial results, highlighting core revenue growth but also reporting GAAP losses and providing 2025 guidance.

Summary

• Fulgent Genetics reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Full year total revenue was $283.5 million.
• Full year core revenue grew 7% year-over-year to $281.2 million.
• The company ended 2024 with $828.6 million in cash, cash equivalents, restricted cash, and investments in marketable securities, representing $26.87 cash per share.
• Fourth quarter total revenue was $76.2 million.
• Fourth quarter core revenue grew 14% year-over-year to $76.0 million.
• The company reported a GAAP loss of $5.9 million, or ($0.19) per share for the fourth quarter.
• Non-GAAP income for the fourth quarter was $1.2 million, or $0.04 per share.
• Adjusted EBITDA income for the fourth quarter was $0.8 million.
• Cash from operations was $25.0 million for the fourth quarter.
• The company reported a GAAP loss of $42.7 million, or ($1.41) per share for the full year.
• Non-GAAP income for the full year was $15.0 million, or $0.49 per share.
• Adjusted EBITDA loss for the full year was $2.8 million.
• Cash from operations was $21.1 million for the full year.
• For the full year 2025, Fulgent expects core revenue of approximately $310 million.
• Fulgent expects a GAAP loss of approximately ($1.95) per share for 2025.
• Fulgent expects a Non-GAAP loss of approximately ($0.65) per share for 2025.
• The company anticipates having approximately $780 million in cash, cash equivalents, and investments in marketable securities as of December 31, 2025.

Sentiment

Score: 6

Explanation: The sentiment is mixed. While there's positive core revenue growth and a strong cash position, the GAAP losses and projected losses temper the overall outlook. The progress in therapeutics development is a positive sign for the long term.

Positives

• Core revenue is growing, indicating strength in the underlying business.
• The company has a substantial cash balance, providing financial flexibility.
• The therapeutics development business is advancing with clinical trials underway.
• The company's laboratory services exhibited strong growth for the year.

Negatives

• The company reported a GAAP loss for both the fourth quarter and the full year 2024.
• The company is projecting a GAAP loss for the full year 2025.
• Adjusted EBITDA was a loss for the full year 2024.

Risks

• Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the company's ongoing stock repurchase program or other expenditures outside the ordinary course of business, which could include M&A.
• The company's success depends on market adoption of its tests and its ability to maintain turnaround times.
• The company faces risks related to volatility in its results and the composition of its customer base.
• The company's success depends on obtaining coverage and adequate reimbursement from third-party payors.
• The company's success depends on the success of its development efforts, including the company's ability to progress its candidates through clinical trials on the timelines expected.
• The company's compliance with the various evolving and complex laws and regulations applicable to its business and its industry is a risk.
• The company's ability to protect its proprietary technology and intellectual property is a risk.

Future Outlook

Fulgent expects core revenue of approximately $310 million for the full year 2025 and anticipates having approximately $780 million in cash, cash equivalents, and investments in marketable securities as of December 31, 2025. The company also projects a GAAP loss of approximately ($1.95) per share and a Non-GAAP loss of approximately ($0.65) per share for 2025.

Management Comments

• Ming Hsieh, Chairperson of the Board of Directors and Chief Executive Officer, said, 'I am pleased with the progress of our business in 2024. Laboratory Services exhibited strong growth for the year. In Therapeutics Development, we now have a clinical pipeline, with FID-007 continuing to progress in a Phase 2 trial and FID-022 cleared by the U.S. FDA to begin a Phase 1 trial.'
• Paul Kim, Chief Financial Officer, said, 'We are pleased with our financial performance in 2024 and believe we have entered 2025 in a position of strength, with projected growth in our laboratory services business and a strong balance sheet to execute our objectives.'

Industry Context

Fulgent is operating in the competitive genetic testing and precision medicine industry, where companies are focused on developing diagnostic and therapeutic solutions for various diseases, particularly in oncology. The company's strategic vision is to become a one-stop solution for cancer care, integrating diagnostics and therapeutics.

Comparison to Industry Standards

• Fulgent's core revenue growth of 7% year-over-year is a key metric to compare against other genetic testing companies like Exact Sciences (which focuses on cancer diagnostics) or Invitae (which offers a range of genetic tests).
• The $828.6 million in cash and investments provides a strong base for future growth and acquisitions, putting Fulgent in a competitive position compared to companies with less financial flexibility.
• The development of FID-007 and FID-022 places Fulgent in the pharmaceutical space, where companies like Roche and Novartis are major players in cancer therapeutics.
• The company's focus on a nano-drug delivery platform is a differentiating factor, potentially offering advantages over traditional drug delivery methods used by other pharmaceutical companies.

Stakeholder Impact

• Shareholders will be impacted by the GAAP losses, but may be encouraged by the core revenue growth and therapeutics pipeline progress.
• Employees may see opportunities for growth in the laboratory services and therapeutics development areas.
• Customers will benefit from the expanding test menu and potential new therapeutic options.
• Suppliers may see increased demand as the company grows its operations.

Next Steps

• Continue Phase 2 trial for FID-007 and present interim clinical data at ASCO 2025.
• Begin Phase 1 trial for FID-022 in Q2 2025.
• Execute on growth strategy, including organic and inorganic initiatives.
• Monitor cash expenditures and manage the stock repurchase program.

Key Dates